
-
Lions not invincible says former All Blacks coach Foster
-
Markets rise as Trump sends tariff letters, delays deadline
-
Australia-born Lion Hansen faces 'pinch-me' moment against old team
-
Mitre by mitre: N. Macedonian nuns craft priceless holy headwear
-
S.Leone islanders despair as rising ocean threatens survival
-
Bulgaria to get final green light to adopt euro in 2026
-
Major garment producer Bangladesh seeks deal after 35% US tariff
-
France's Macron kicks off pomp-filled UK state visit
-
Mbappe and PSG set for Club World Cup reunion as Real Madrid eye final
-
US to send 'more weapons' to Ukraine: Trump
-
Most markets rise as Trump sends tariff letters, delays deadline
-
Slovak gunman who shot PM to go on trial
-
As heatwaves intensify, Morocco ups effort to warn residents
-
All Blacks captain Scott Barrett out for rest of France series
-
AI video becomes more convincing, rattling creative industry
-
Trump says new tariff deadline 'not 100 percent firm'
-
Trump hosts Netanyahu in push for Gaza deal
-
Alpha males are rare among our fellow primates: scientists
-
At least 10 dead in Kenya during protests after heavy police deployment
-
Star Copper Confirms Two Prospective Copper Zones and Identifies Large Magnetic Anomaly as Daily Drilling Continues
-
Nano One Positioned for Rising LFP Demand, Aligned with Energy Strategies & Supporting Critical Mineral Localization Efforts Worldwide
-
Karbon-X Becomes Official Name Sponsor of BK Dukes Basketball Team
-
Angle PLC Announces Parsortix Enables Study Of Cancer Progression
-
Empire Metals Limited Announces Completion of MRE Drilling Campaign
-
Lobe Sciences Announces Validation of European Unitary Patent for DHA-Based Composition for Sickle Cell Disease
-
Alcaraz, Sabalenka headline action in Wimbledon quarter-finals
-
Trump unveils first wave of steeper US tariffs, extends deadline
-
Knicks hire two-time NBA Coach of the Year Brown to guide club
-
Medical groups sue US health secretary over Covid-19 vaccine change
-
Now 48, man becomes 140th 'stolen grandchild' tracked in Argentina
-
Sinner wins Wimbledon reprieve after Dimitrov injury heartbreak, Djokovic survives
-
Trump unveils first wave of steeper US tariffs in push for deals
-
Swiss MLS goalie Frei resting at home after on-field collision
-
Relentless Spain reach Euro 2025 quarters after thumping Belgium
-
US stocks retreat from records on Trump tariff deluge
-
MLB Nationals name Cairo interim manager after shake-up
-
Sinner into Wimbledon quarter-finals after injury heartbreak for Dimitrov
-
Pacers guard Haliburton will miss entire '25-26 NBA season
-
Texas floods: How geography, climate and policy failures collided
-
Sinner into Wimbledon quarters after injured Dimitrov retires
-
UN General Assembly condemns 'systematic oppression' of women in Afghanistan
-
Epstein died by suicide, did not have 'client list': govt memo
-
Trump, Brazil's Lula clash over politically charged coup trial
-
Trump to meet Netanyahu in push for Gaza deal
-
Swiatek into Wimbledon quarter-finals
-
High-speed fall forces Philipsen out of Tour de France
-
Trump says to slap allies Japan, South Korea with 25% tariffs
-
Maresca shrugs off heat concerns as Chelsea face 'ugly duckling' Fluminense
-
Youth camp confirms 27 dead as Texas flood toll passes 90
-
US revoking 'terrorist' designation for Syria's HTS

PetVivo Holdings, Inc. Announces Participation in The Microcap Conference 2025
PetVivo Holdings, Inc. (OTCQB:PETV, PETVW), a leading provider of medical devices and biomedical therapeutics for equines and companion animals, is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ.
John Lai, Chief Executive Officer of PetVivo Holdings, Inc. will provide a Company overview as well as discuss its lead product, SPRYNG™ with OsteoCushion™ Technology. Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal's subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
About The Microcap Conference 2025
The Microcap Conference is the largest independent microcap event in the U.S., bringing together top-tier investors and executives from microcap companies. The event offers a platform for companies to showcase their value propositions through presentations, one-on-one meetings, and networking opportunities.
The 2025 event will feature:
Keynote Speakers: Renowned industry figures, including Jon Ledecky, Co-Owner of the New York Islanders, who will engage in a fireside chat with CNBC's Bob Pisani; plus Tom Gardner, CEO of Motley Fool, who will share insights on investing, market trends, and entrepreneurial success.
Expert Panels and Presentations: Financial commentators Ron Insana (CNBC) and Charlie Gasparino (FOX Business) will cover critical topics for the US equity markets, from capital formation to regulatory updates and market trends.
Entertainment Headliner: A special performance by Tom Papa, celebrated comedian and host of Netflix specials, ensuring a memorable evening for attendees.
Hosted by DealFlow Events, The Microcap Conference is renowned for its blend of high-quality content, engaging networking, and exceptional entertainment. For more information, visit https://themicrocapconference.com.
About PetVivo Holdings
PetVivo Holdings, Inc. (OTCQB:PETV, PETVW) is a biomedical device company focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The company is pursuing a strategy of developing and commercializing human therapies for the treatment of companion animals in capital and time efficient ways. A key component of this strategy is an accelerated timeline to revenues for veterinary medical devices that can enter the market much earlier than more stringently regulated human pharmaceuticals and biologics.
PetVivo has developed a robust pipeline of products for the medical treatment of animals and people, with a portfolio of 21 patents that protect the company's biomaterials, products, production processes and methods of use. The company's commercially launched flagship product, Spryng™ with OsteoCushion™ Technology, is a veterinarian-administered, intra-articular injectable designed for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses.
For more information about PetVivo and its revolutionary Spryng with OsteoCushion Technology, email [email protected] or visit petvivo.com or sprynghealth.com.
Disclosure Information
PetVivo uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company's Investor Relations website, in addition to following the company's press releases, SEC filings, public conference calls, presentations and webcasts.
Forward-Looking commercial Statements
The foregoing information regarding PetVivo Holdings, Inc. (the "Company") may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company's proposed development and commercial timelines, and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company's business are described in detail in the Company's Annual Report on Form 10-K for the year ended March 31, 2024 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216
SOURCE: PetVivo Holdings, Inc.
P.Stevenson--AMWN